Bladder Cancer from Detection to Treatment


What Is Bladder Cancer?

Bladder cancer begins in the cells lining the inside of the bladder - the organ that stores urine.

The most common type is Urothelial | Transitional Cell | Carcinoma.

It is often detected early because symptoms like blood in the urine appear quickly.


1. Initial Detection / Screening

Common Symptoms:
Blood in urine | hematuria.
Painful urination | dysuria.
Frequent urination or urgency.
Pelvic or lower back pain.
Fatigue or weight loss in later stages.

Screening:
There is no routine population screening for bladder cancer.
High-risk individuals may have urine cytology or cystoscopy periodically.


2. Diagnostic Testing

Urine Tests
Urinalysis
Urine cytology
Urine tumor marker tests

Imaging Studies
Ultrasound
CT Urography / Intravenous Urogram
MRI

Cystoscopy
A thin camera | cystoscope | is inserted through the urethra to visually inspect the bladder.
Biopsy or transurethral resection is performed during cystoscopy to remove tumor tissue for histological analysis.


3. Pathology and Staging

Histological Types
Urothelial carcinoma
Squamous cell carcinoma
Adenocarcinoma

Tumor Grading
Low-grade:
slower growth, less likely to invade.

High-grade:
aggressive, more likely to invade or spread.

Staging - TNM System
Ta: Non-invasive papillary tumor | inner lining only.
T1: Invades connective tissue under the lining.
T2: Invades muscle layer.
T3: Extends into fatty tissue outside the bladder.
T4: Invades nearby organs | prostate, uterus, pelvic wall.
N/M: Lymph node or distant metastasis involvement.

Grouped Stages
Non–muscle-invasive:
Ta, T1, carcinoma in situ.

Muscle-invasive:
T2 and above.

Metastatic:
cancer spread beyond bladder.


4. Treatment Options

Non–Muscle-Invasive Bladder Cancer

Transurethral Resection of Bladder Tumor
Removes tumor through cystoscope.
Diagnostic and therapeutic.

Intravesical Therapy
Medicine placed directly into bladder via catheter.
Mitomycin C or Bacillus Calmette - Guérin used to kill remaining cancer cells and prevent recurrence.
BCG is most effective for high-risk NMIBC.

Regular Cystoscopic Surveillance
Every 3-6 months initially, then yearly.

Muscle-Invasive Bladder Cancer

Radical Cystectomy
Removal of entire bladder and nearby lymph nodes.

In men:
often includes prostate and seminal vesicles.

In women:
uterus, ovaries, and part of vagina may be removed.

Urinary diversion created.

Chemotherapy
Neoadjuvant - before surgery
Adjuvant - after surgery

Bladder-Preserving Therapy
Trimodal therapy: TURBT + chemotherapy + radiation therapy

Metastatic or Advanced Disease

Systemic chemotherapy
Cisplatin-based regimens | MVAC or GC.

Immunotherapy
Pembrolizumab, Nivolumab, Atezolizumab

Targeted therapy
Erdafitinib for FGFR mutations.

Palliative radiation therapy
To relieve symptoms | pain, bleeding, obstruction.


5. Follow-Up and Monitoring

Cystoscopy
Every 3-6 months for the first 2 years.
Every 6-12 months afterward.

Urine cytology and imaging:
CT or ultrasound
Periodically to monitor recurrence or metastasis.

Lifestyle changes:
Quit smoking.
Maintain hydration.
Avoid exposure to industrial chemicals | aromatic amines.